Partnerships Propel Precision Medicine Forward
Precision medicine is entering a new phase, one driven not only by scientific innovation, but by the partnerships, acquisitions and collaborations needed to bring biomarker-driven care to patients at scale.
Recent industry moves highlight this growing momentum:
1
Natera's Signatera™ CDx received FDA approval, marking a major milestone for ctDNA and MRD-guided treatment selection.
2
Roche acquired PathAI, strengthening its capabilities in AI-powered pathology and companion diagnostics.
3
Leica Biosystems, AstraZeneca and Daiichi Sankyo expanded their collaboration to develop AI-enabled diagnostic approaches for precision oncology.
4
Tempus AI acquired Personalis, further accelerating the convergence of AI, molecular diagnostics and precision oncology.
5
Gilead Sciences and Nucleai announced a large-scale collaboration to leverage AI-powered tissue intelligence, spatial biology and computational pathology to advance biomarker discovery across Gilead's oncology ADC programs.
The recent activity across the sector points to a common theme: precision medicine is becoming increasingly data-rich, multimodal and diagnostics-led.
From FDA approval of MRD-guided treatment selection, to growing investment in AI-powered pathology, tissue intelligence and computational biomarker discovery, companies are looking beyond single biomarkers to generate deeper biological insight and improve patient stratification.
These conversations will continue at the 16th World Clinical Biomarkers & Companion Diagnostics Summit, where speakers from Roche, AstraZeneca, Daiichi Sankyo, Natera, Tempus AI, Gilead Sciences and Nucleai will share how they are advancing biomarker discovery, companion diagnostics and precision medicine adoption.
Unite with us this October to hear directly from the organizations shaping the next wave of biomarker-driven healthcare.